Drugs / recombinant vaccinia-TRICOM vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00071942 | Oct 2003 → Nov 2007 | male breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00022568 | Aug 2001 → ? | cutaneous melanoma | Herbert Irving Comprehensive Cancer Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant vaccinia-TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00022568 ↗ |
| Known as | rV-Tricom | “A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma” NCT00022568 ↗ |
| Modality | Vaccine | “recombinant vaccinia-TRICOM vaccine” NCT00022568 ↗ |